What is a medically supervised injecting room and how does it actually work?

A medically supervised injecting room (MSIR) is a health facility where people who use illicit drugs can bring and consume their own substances under clinical supervision, with staff trained to recognise and respond to overdose. The facility does not supply drugs. Melbourne's North Richmond MSIR opened in 2018 and operates as a permanent health service. In an overdose, staff can administer naloxone, provide oxygen, and arrange emergency transfer if needed. The facility also connects clients with addiction medicine, housing, social work, and other services — harm reduction as a gateway to broader care, rather than an endpoint.

Does evidence like this mean supervised injecting facilities increase drug use in the area?

The available evidence does not support that conclusion. The Monash study tracked nine years of ambulance data across Victoria and found the 71% callout reduction was geographically concentrated around the MSIR. If the facility were attracting a larger drug-using population to the area, you would expect callout rates to rise or remain flat — not fall steeply. Research from Sydney's facility and from international counterparts in Switzerland, the Netherlands, and Canada similarly does not show increased drug use in surrounding areas. The mechanism is prevention of death and injury among people already using, alongside pathways into treatment.

71% fewer heroin callouts: Melbourne injecting room evidence is in

What just happened

A nine-year study from Monash University and Turning Point has provided the strongest Australian evidence yet that supervised injecting facilities reduce population-level opioid harm. Published this week in the International Journal of Drug Policy, the research analysed 24,701 heroin-related ambulance attendances across Victoria between 2015 and 2023 — before and after Melbourne’s North Richmond Medically Supervised Injecting Room (MSIR) opened in 2018.

The headline number: heroin-related ambulance callouts in the MSIR catchment area fell by 71% after the facility opened. That is a drop from approximately 48 callouts per month to 14. The catchment area had previously recorded callout rates six times higher than central Melbourne and 40 times higher than the rest of Victoria. After 2018, that gap closed substantially.

The research team noted that similar trends were absent in central Melbourne and statewide, which is the critical methodological detail. It suggests the MSIR itself — not a broader shift in heroin use patterns — was driving the change.

Since opening, the North Richmond MSIR has recorded over 600,000 visits, managed more than 11,000 overdose incidents, and conducted over 177,000 health and social support interventions. Zero overdose deaths have occurred inside the facility.

The both-and

The evidence has been building for a while — and is now robust for Australia

Sydney’s Kings Cross facility has operated since 2001, managing nearly 11,000 overdose events without deaths among almost 18,000 registered clients. The international literature from Switzerland, the Netherlands, Germany, and Canada is consistent: supervised injecting facilities reduce overdose deaths, reduce emergency service burden, and do not increase drug use in surrounding areas.

What the Monash study adds is a nine-year longitudinal dataset from a contemporary Australian context, with a methodological design — geographic comparison, interrupted time series — that explicitly tests whether the MSIR itself drove the change. Associate Professor Bosco Rowland called it “the strongest Australian evidence yet.” Professor Dan Lubman, who directs Turning Point, noted the facility “is not only saving lives inside the facility — it is reducing the burden of heroin-related emergencies on ambulance services.”

This is not a case where the evidence is preliminary, contested within the research community, or relying on selected international data. The data is Australian, longitudinal, peer-reviewed, and internally consistent.

The policy debate remains unresolved — and that is worth naming

The evidence is one thing. The policy environment is another.

In 2024, Victoria’s government decided not to open a second supervised injecting room in Melbourne’s CBD, despite the MSIR evidence and calls from health and addiction medicine advocates. The decision reflected a particular reading of the political calculus — concern about community and media reactions in an inner-city electorate — rather than a scientific dispute about whether the intervention works.

That distinction matters. When a government declines to expand an evidence-based intervention, it is making a political choice, not a scientific one. Both things can be true simultaneously: the evidence supports expansion, and the political will is currently absent. Neither statement invalidates the other.

For someone on the fence, it is also worth understanding what these facilities are not arguing. They are not arguing that heroin use is good, that abstinence is the wrong goal, or that treatment does not work. They are arguing that among people who are using now, not dying is better than dying — and that staying alive is the precondition for any future recovery. That is a position that most people, regardless of their views on drug policy, can find something in.

What it means for emergency services and GPs

The ambulance data from the Monash study represents a real reduction in emergency resource draw. Fewer heroin overdose callouts in North Richmond means more ambulance capacity for cardiac events, falls, trauma, and stroke. That is a downstream benefit that extends beyond people who use drugs.

In general practice, the interface is harm reduction referral. GPs working with patients who use opioids — whether heroin, pharmaceutical opioids used outside prescribed parameters, or fentanyl analogues — can refer to an MSIR as a health contact point. The MSIR connects clients with addiction medicine, general practice, housing, and social services. It is a entry point into the health system for people who might otherwise have no contact with it.

2 cents

If you have never considered where you stand on supervised injecting rooms, this week’s data is a good starting point. The moral argument (are we condoning drug use?) and the empirical argument (does this reduce harm?) are separate questions. The empirical answer is now well-evidenced in an Australian setting: yes, it reduces harm, measurably, in the surrounding population.

Where that leaves Australian health policy — and how many more facilities the evidence justifies — is a legitimate debate. But the debate should be had with the evidence on the table, not around it.

Verdict: yes — the strongest Australian evidence to date on a consequential public health intervention, from a credible research group, in a peer-reviewed journal.

Sources cited

Medical Republic — Supervised injecting room cuts ambo callouts by 71%. https://www.medicalrepublic.com.au/supervised-injecting-room-cuts-ambo-callouts-by-71/127187
newsGP (RACGP) — Supervised injecting room linked to dramatic fall in heroin callouts. https://www1.racgp.org.au/newsgp/clinical/supervised-injecting-room-linked-to-dramatic-fall
International Journal of Drug Policy — Monash University / Turning Point (9-year Victorian ambulance data study). https://www.journals.elsevier.com/international-journal-of-drug-policy